Vertex Pharmaceuticals Inc Asset Resilience Ratio
Vertex Pharmaceuticals Inc asset resilience ratio. Vertex Pharmaceuticals Inc (VRTX) has an Asset Resilience Ratio of 6.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vertex Pharmaceuticals Inc (VRTX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vertex Pharmaceuticals Inc (2000–2025)
Asset resilience ratio of Vertex Pharmaceuticals Inc from 2000 to 2025. This chart shows how Vertex Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read debt load of Vertex Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vertex Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VRTX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.71 Billion | 6.23% |
| Total Liquid Assets | $1.71 Billion | 6.23% |
Asset Resilience Insights
- Limited Liquidity: Vertex Pharmaceuticals Inc maintains only 6.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vertex Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Vertex Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Vertex Pharmaceuticals Inc Asset Resilience Ratio by Year (2000–2025)
Vertex Pharmaceuticals Inc asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Vertex Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.83% | $1.52 Billion | $26.14 Billion | -1.04pp |
| 2024-12-31 | 6.86% | $1.55 Billion | $22.53 Billion | +3.13pp |
| 2023-12-31 | 3.74% | $849.20 Million | $22.73 Billion | +2.22pp |
| 2022-12-31 | 1.51% | $274.50 Million | $18.15 Billion | -3.92pp |
| 2021-12-31 | 5.43% | $729.90 Million | $13.43 Billion | -0.27pp |
| 2020-12-31 | 5.71% | $670.70 Million | $11.75 Billion | -2.70pp |
| 2019-12-31 | 8.40% | $698.97 Million | $8.32 Billion | +0.11pp |
| 2018-12-31 | 8.30% | $518.11 Million | $6.25 Billion | -3.64pp |
| 2017-12-31 | 11.94% | $423.25 Million | $3.55 Billion | +3.28pp |
| 2016-12-31 | 8.66% | $250.61 Million | $2.89 Billion | -4.46pp |
| 2015-12-31 | 13.12% | $327.69 Million | $2.50 Billion | -19.49pp |
| 2014-12-31 | 32.61% | $761.85 Million | $2.34 Billion | -6.02pp |
| 2013-12-31 | 38.63% | $895.78 Million | $2.32 Billion | +8.48pp |
| 2012-12-31 | 30.15% | $831.81 Million | $2.76 Billion | +7.75pp |
| 2011-12-31 | 22.39% | $493.60 Million | $2.20 Billion | -23.29pp |
| 2010-12-31 | 45.68% | $788.21 Million | $1.73 Billion | +2.82pp |
| 2009-12-31 | 42.87% | $838.25 Million | $1.96 Billion | -2.31pp |
| 2008-12-31 | 45.18% | $442.99 Million | $980.48 Million | +27.69pp |
| 2007-12-31 | 17.49% | $105.21 Million | $601.48 Million | -35.84pp |
| 2006-12-31 | 53.33% | $491.45 Million | $921.58 Million | +1.76pp |
| 2005-12-31 | 51.57% | $283.11 Million | $549.00 Million | -10.27pp |
| 2004-12-31 | 61.84% | $337.31 Million | $545.45 Million | -5.11pp |
| 2003-12-31 | 66.95% | $485.00 Million | $724.41 Million | +2.36pp |
| 2002-12-31 | 64.59% | $526.89 Million | $815.72 Million | +4.71pp |
| 2001-12-31 | 59.88% | $554.00 Million | $925.13 Million | +51.28pp |
| 2000-12-31 | 8.61% | $66.51 Million | $772.88 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more